SC
TVRD

Savant Capital’s Tvardi Therapeutics TVRD Stock Holding History

Savant Capital’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$49.4K Buy
+19,462
New +$61K ﹤0.01% 1827

Other funds holding TVRD

AFG
American Financial Group Cincinnati, Ohio $284M AUM 12.01% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
DWAM
Duncan Williams Asset Management Memphis, Tennessee $444M AUM 24.78% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
AAP
Arax Advisory Partners Denver, Colorado $15.1B AUM 27.93% 1-Year Est. Return
PAP
Persistent Asset Partners Hong Kong $335M AUM 275.57% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $202B AUM 37.79% 1-Year Est. Return

Savant Capital's TVRD Position: Q2 2026 in Review

Savant Capital opened a new position in Tvardi Therapeutics (TVRD) in Q2 2026: 19,462 shares worth $49.4K. The stake represents ﹤0.01% of the portfolio and ranks #1827 among its holdings.

34 funds tracked by Wall St. Rank hold TVRD as of Q2 2026.

  • Savant Capital held 19,462 shares of Tvardi Therapeutics worth $49.4K as of Q2 2026.
  • Tvardi Therapeutics was a new Savant Capital position in Q2 2026.
  • Tvardi Therapeutics made up ﹤0.01% of Savant Capital's portfolio in Q2 2026, its #1827 holding.
  • 34 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q2 2026.

Based on Savant Capital's 13F filing for Q2 2026, filed 10 Aug 2026.